Literature DB >> 22331638

Severe necroinflammatory reaction caused by natural killer cell-mediated Fas/Fas ligand interaction and dendritic cells in human hepatocyte chimeric mouse.

Akihito Okazaki1, Nobuhiko Hiraga, Michio Imamura, C Nelson Hayes, Masataka Tsuge, Shoichi Takahashi, Hiroshi Aikata, Hiromi Abe, Daiki Miki, Hidenori Ochi, Chise Tateno, Katsutoshi Yoshizato, Hideki Ohdan, Kazuaki Chayama.   

Abstract

UNLABELLED: The necroinflammatory reaction plays a central role in hepatitis B virus (HBV) elimination. Cluster of differentiation (CD)8-positive cytotoxic T lymphocytes (CTLs) are thought to be a main player in the elimination of infected cells, and a recent report suggests that natural killer (NK) cells also play an important role. Here, we demonstrate the elimination of HBV-infected hepatocytes by NK cells and dendritic cells (DCs) using urokinase-type plasminogen activator/severe combined immunodeficiency mice, in which the livers were highly repopulated with human hepatocytes. After establishing HBV infection, we injected human peripheral blood mononuclear cells (PBMCs) into the mice and analyzed liver pathology and infiltrating human immune cells with flow cytometry. Severe hepatocyte degeneration was observed only in HBV-infected mice transplanted with human PBMCs. We provide the first direct evidence that massive liver cell death can be caused by Fas/Fas ligand (FasL) interaction provided by NK cells activated by DCs. Treatment of mice with anti-Fas antibody completely prevented severe hepatocyte degeneration. Furthermore, severe hepatocyte death can be prevented by depletion of DCs, whereas depletion of CD8-positive CTLs did not disturb the development of massive liver cell apoptosis.
CONCLUSION: Our findings provide the first direct evidence that DC-activated NK cells induce massive HBV-infected hepatocyte degeneration through the Fas/FasL system and may indicate new therapeutic implications for acute severe/fulminant hepatitis B.
Copyright © 2012 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22331638     DOI: 10.1002/hep.25651

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  18 in total

Review 1.  Experimental models and therapeutic approaches for HBV.

Authors:  Maura Dandri; Marc Lütgehetmann; Jörg Petersen
Journal:  Semin Immunopathol       Date:  2012-08-17       Impact factor: 9.623

Review 2.  Modulators of innate immunity as novel therapeutics for treatment of chronic hepatitis B.

Authors:  Aleksei Suslov; Stefan Wieland; Stephan Menne
Journal:  Curr Opin Virol       Date:  2018-02-20       Impact factor: 7.090

3.  Deletion of Mir155 prevents Fas-induced liver injury through up-regulation of Mcl-1.

Authors:  Weina Chen; Chang Han; Jinqiang Zhang; Kyoungsub Song; Ying Wang; Tong Wu
Journal:  Am J Pathol       Date:  2015-04       Impact factor: 4.307

4.  miR-223 Deficiency Protects against Fas-Induced Hepatocyte Apoptosis and Liver Injury through Targeting Insulin-Like Growth Factor 1 Receptor.

Authors:  Ximena V Qadir; Weina Chen; Chang Han; Kyoungsub Song; Jinqiang Zhang; Tong Wu
Journal:  Am J Pathol       Date:  2015-12       Impact factor: 4.307

5.  Human Cytotoxic T Lymphocyte-Mediated Acute Liver Failure and Rescue by Immunoglobulin in Human Hepatocyte Transplant TK-NOG Mice.

Authors:  Takuro Uchida; Nobuhiko Hiraga; Michio Imamura; Masataka Tsuge; Hiromi Abe; C Nelson Hayes; Hiroshi Aikata; Yuji Ishida; Chise Tateno; Katsutoshi Yoshizato; Hideki Ohdan; Kazunari Murakami; Kazuaki Chayama
Journal:  J Virol       Date:  2015-08-05       Impact factor: 5.103

Review 6.  Natural killer cells in liver disease.

Authors:  Zhigang Tian; Yongyan Chen; Bin Gao
Journal:  Hepatology       Date:  2013-04       Impact factor: 17.425

Review 7.  Natural Killer Cells and Liver Fibrosis.

Authors:  Frank Fasbender; Agata Widera; Jan G Hengstler; Carsten Watzl
Journal:  Front Immunol       Date:  2016-01-29       Impact factor: 7.561

8.  Tissue-Resident NK Cells Mediate Ischemic Kidney Injury and Are Not Depleted by Anti-Asialo-GM1 Antibody.

Authors:  Francisco Victorino; Dorothy K Sojka; Kelley S Brodsky; Eoin N McNamee; Joanne C Masterson; Dirk Homann; Wayne M Yokoyama; Holger K Eltzschig; Eric T Clambey
Journal:  J Immunol       Date:  2015-10-09       Impact factor: 5.422

Review 9.  Immunopathology of Chronic Hepatitis B Infection: Role of Innate and Adaptive Immune Response in Disease Progression.

Authors:  Arshi Khanam; Joel V Chua; Shyam Kottilil
Journal:  Int J Mol Sci       Date:  2021-05-23       Impact factor: 5.923

10.  NK cells: a double-edged sword in chronic hepatitis B virus infection.

Authors:  Mala K Maini; Dimitra Peppa
Journal:  Front Immunol       Date:  2013-03-01       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.